Annovis Bio Inc. (NYSE: ANVS), a clinical-stage biotechnology company focused on neurodegenerative diseases, has announced it will host a corporate update webinar on Sept. 2, 2026, at 4 p.m. EDT. The webinar, led by founder, president and CEO Maria Maccecchini, Ph.D., will cover recent progress, ongoing clinical programs and upcoming milestones, including the fully enrolled pivotal Phase 3 Alzheimer's disease (AD) trial, with top-line data and regulatory submissions expected in 2027.
The company is developing buntanetap, an investigational once-daily oral therapy designed to inhibit the translation of multiple neurotoxic proteins, including APP, amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients.
Key updates to be discussed include the initiation of an AD open-label study in October 2026 to generate long-term safety data. Additionally, the company's Parkinson's disease (PD) open-label study is already underway, and discussions are continuing regarding the initiation of a Parkinson's disease dementia program. These developments are part of Annovis's broader strategy to advance treatments for Alzheimer's and Parkinson's diseases, which affect millions worldwide.
The webinar will be followed by a live question-and-answer session, providing investors and stakeholders an opportunity to engage with the company's leadership. This corporate update comes at a critical juncture as the biotechnology sector continues to face high attrition rates in neurodegenerative disease trials, making the progress of Annovis's Phase 3 AD trial particularly significant.
The company, headquartered in Malvern, Pennsylvania, is a Phase 3 clinical-stage biotechnology company. Its lead drug candidate, buntanetap (formerly posiphen), is being investigated for its potential to modify the course of these debilitating diseases. The upcoming data readout from the Phase 3 AD trial could have substantial implications for the field, potentially offering a new therapeutic approach that targets multiple toxic proteins simultaneously.
For more information about the webinar and the company, visit the full press release at https://ibn.fm/mls3F or the company's website at www.annovisbio.com. Investors and interested parties can also access additional news and updates in the company's newsroom at https://ibn.fm/ANVS.
The announcement underscores the importance of ongoing research into treatments for neurodegenerative diseases, which represent a growing public health challenge. With an aging global population, the need for effective therapies for Alzheimer's and Parkinson's diseases is more urgent than ever. Annovis's efforts to address the underlying causes of these conditions, rather than just managing symptoms, could mark a significant shift in the approach to treating these complex disorders.
